Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Iparomlimab and Tuvonralimab (QL1706) with chemotherapy in previously untreated advanced or metastatic gastric can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Gastric Cancer (GC), Gastroesophageal Junction Cancer | Phase 2 | Status: RECRUITING